Artivion Earnings Call Highlights Growth, Margin Momentum

Artivion Inc. ((AORT)) has held its Q4 earnings call. Read on for the main highlights of the call.

Artivion’s latest earnings call struck a largely upbeat tone as management highlighted robust revenue expansion, accelerating EBITDA growth, and improving leverage alongside strong clinical and regulatory milestones. While cyber fallout, tissue softness, Italian reimbursement noise, and heavier CapEx and R&D weigh on the near term, executives argued these are manageable against a clearer path to 2026 targets.

Double-Digit Full-Year Growth and Margin Expansion

Artivion reported 2025 adjusted constant currency revenue of $443.6 million, up 13% year over year, underscoring durable demand across its portfolio. Adjusted EBITDA climbed 26%, lifting the margin 190 basis points to 20.2% and signaling that operating leverage is starting to come through despite targeted investment.

Fourth Quarter Acceleration in Sales and Profitability

Fourth quarter adjusted revenue reached $118.3 million, excluding the Italian payback impact, an 18.5% year-over-year jump that capped the year on a strong note. Adjusted EBITDA for the quarter rose from $17.6 million to $22.7 million, with margin improving to 19.2%, about 110 basis points higher than a year earlier.

Stent Grafts Emerge as a Core Growth Engine

Stent graft revenue surged 36% year over year in the fourth quarter on a constant currency basis, or 28% when normalizing for the 2024 cyber incident, making the franchise a key growth pillar. Management spotlighted plans to deepen commercialization in the U.S. and Japan, positioning stent grafts as a foundational driver of the company’s medium-term trajectory.

On-X Valve Growth and Expanding Market Opportunity

On-X delivered 24% constant currency revenue growth in the fourth quarter, reflecting strong adoption and clinical confidence in the platform. Executives project mid-teens growth for On-X in 2026 and see roughly $100 million of incremental U.S. market potential based on emerging clinical data that could broaden its addressable patient pool.

Clinical Wins and Regulatory Progress Build Future Optionality

Management underscored positive data from the AMDS PERSEVERE two-year readout and NEXUS TRIUMPH one-year IDE results, which showed high survival and low stroke and renal intervention rates. The company has submitted the fourth and final AMDS PMA module and is targeting PMA completion around mid-2026, while outlining timelines for NEXUS and other PMA pathways that underpin its innovation story.

Broad-Based Regional Momentum Across Global Markets

Geographic performance was strong and well balanced in the fourth quarter, with Asia Pacific leading at 32% constant currency growth, followed by North America at 18% and EMEA at 17%. Latin America posted 9% growth, reinforcing the view that Artivion’s portfolio is gaining traction globally rather than relying on a single region or product line.

Deleveraging Strengthens the Balance Sheet

Artivion ended the year with approximately $64.9 million in cash and $215.1 million in debt, giving the company increased flexibility to fund growth projects. The net leverage ratio improved sharply to 1.8 times from 3.8 times a year earlier, pointing to meaningful deleveraging and reducing balance sheet risk as the pipeline advances.

Italian Cyber Incident and Tissue Business Headwinds

The 2024 cybersecurity incident reduced fourth quarter revenue by about $4.5 million, split between stent grafts and tissue processing, and continues to complicate year-over-year comparisons. Tissue processing posted 6% constant currency growth in the quarter, but adjusting for prior-year cyber effects, volumes declined 4% and full-year tissue revenue fell 3%, leaving this legacy segment below expectations.

Italian Payback and Manufacturing Weigh on Margins

A $2.3 million revenue adjustment tied to Italian payback obligations from 2019 to 2025 was stripped from adjusted revenue but reduced reported gross margin and introduced added uncertainty in markets outside the U.S. Gross margin for the quarter held at 63%, with roughly one percentage point drag from the Italian item and additional pressure from manufacturing inefficiencies on top of prior cyber-related idle plant costs.

Free Cash Flow Dampened by Strategic Investments

Despite solid profitability, full-year free cash flow was modest at about $1 million as Artivion prioritized strategic spending over near-term cash generation. Roughly $20 million of one-time cash outlays to acquire two facilities in Austin, combined with elevated capital investment, weighed on reported free cash flow but are intended to support long-term capacity and growth.

CapEx and R&D Spending to Rise

Looking ahead, capital expenditures are expected to increase to around $50 million in 2026 from $39 million in 2025, funding On-X manufacturing capacity and systems upgrades. R&D is projected to rise to roughly 8% of sales, about 100 basis points higher, which management acknowledged will temporarily temper EBITDA leverage relative to its long-term ambition of doubling revenue into EBITDA.

Commercialization Risks for AMDS and NEXUS

Management cautioned that new product launches are still at an early stage, with AMDS currently opened in only about 10% of target accounts and constrained by administrative hurdles tied to HDE and local IRB processes. NEXUS will focus on a smaller group of high-volume centers and demands more intensive training, raising the possibility of uneven adoption and timing risk even as clinical data look compelling.

Longer-Term Pipeline and TAM Expansion

Beyond current products, Artivion highlighted the ARTISAN study for the Arecibo LSA device, where eight of 132 patients have been enrolled and completion is expected by mid-2027. Potential FDA approval in 2029 would open an estimated $80 million incremental U.S. market, adding to the company’s longer-term total addressable market alongside opportunities in On-X and stent grafts.

Guidance Signals Continued Growth and Margin Gains into 2026

For 2026, Artivion guided to 10% to 14% constant currency revenue growth, implying reported sales of $486 million to $504 million, and adjusted EBITDA of $105 million to $110 million, or roughly 18% to 22% growth versus 2025. The outlook calls for about 150 basis points of adjusted EBITDA margin expansion, modest gross margin improvement, SG&A leverage, higher R&D and CapEx, slightly positive free cash flow, and faster growth in On-X and stent grafts relative to flat tissue and modest BioGlue gains.

Artivion’s earnings call painted the picture of a medtech company steadily transitioning from recovery to sustained growth, with stent grafts, On-X, and a strengthening balance sheet at the center of the story. Execution risks around new product uptake, tissue softness, and higher investment levels remain, but investors heard a confident case that clinical momentum and operating leverage can carry the stock toward the company’s 2026 objectives.